Wang Jennifer Peyling, Hielscher Abigail
Department of Biomedical Sciences, Georgia-Philadelphia College of Osteopathic Medicine, Suwanee, GA 30024, USA.
J Cancer. 2017 Feb 25;8(4):674-682. doi: 10.7150/jca.16901. eCollection 2017.
Fibronectin is a matrix glycoprotein which has not only been found to be over-expressed in several cancers, but has been shown to participate in several steps of tumorigenesis. The purpose of this review is to illustrate how aberrant fibronectin expression influences tumor growth, invasion, metastasis and therapy resistance. In particular, this review will focus on the interactions between cell receptor ligands and fibronectin and how this interaction influences downstream signaling events that aid tumor progression. This review will further discuss the possible implications of therapeutic drugs directed against fibronectin and/or cellular interactions with fibronectin and will additionally discuss novel approaches by which to limit intra- and extra-tumoral fibronectin expression and the cellular events which lead to aberrant fibronectin expression. It is anticipated that these studies will set a basis for future research that will not only aid understanding of fibronectin and its prognostic significance, but will further elucidate novel targets for therapeutics.
纤连蛋白是一种基质糖蛋白，不仅在多种癌症中过度表达，还参与肿瘤发生的多个步骤。本综述的目的是阐述异常的纤连蛋白表达如何影响肿瘤生长、侵袭、转移和治疗抗性。特别是，本综述将聚焦于细胞受体配体与纤连蛋白之间的相互作用，以及这种相互作用如何影响有助于肿瘤进展的下游信号事件。本综述还将进一步讨论针对纤连蛋白和/或细胞与纤连蛋白相互作用的治疗药物的可能影响，并另外讨论限制肿瘤内和肿瘤外纤连蛋白表达的新方法以及导致异常纤连蛋白表达的细胞事件。预计这些研究将为未来的研究奠定基础，这不仅有助于理解纤连蛋白及其预后意义，还将进一步阐明新的治疗靶点。
